A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells

被引:83
作者
Chen, W
Ohara, N
Wang, JY
Xu, Q
Liu, J
Morikawa, A
Sasaki, H
Yoshida, S
Demanno, DA
Chwalisz, K
Maruo, T
机构
[1] Kobe Univ, Grad Sch Med, Dept Obstet & Gynecol, Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] TAP Pharmaceut Prod Inc, Lake Forest, IL 60045 USA
关键词
D O I
10.1210/jc.2005-2379
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Asoprisnil, a selective progesterone (P4) receptor (PR) modulator (SPRM) with mixed P4 agonist/antagonist activities, reduces uterine leiomyoma volume in a dose-dependent manner in the presence of follicular phase estrogen concentrations. The evidence from clinical studies suggests that asoprisnil may directly target the uterine leiomyomata. Objective and Methods: The present study evaluated the effects of asoprisnil on cell proliferation, the expression of apoptosis-related proteins, and apoptosis in cultured human uterine leiomyoma cells and matched normal myometrial cells. PR-A and PR-B expression in the two types of cells was comparatively evaluated. Cell proliferation, proliferating cell nuclear antigen (PCNA)-positive rate, and TUNEL-positive rate were assessed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H-tetrazolium assay, immunocytochemistry, and terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick end labeling (TUNEL) assay, respectively. The expression of apoptosis-related proteins and PR was assessed by Western blot analysis. Results: Compared with untreated cultures, asoprisnil decreased the number of viable cultured cells, the PCNA-positive rate, and PCNA protein expression in cultured leiomyoma cells. Asoprisnil increased the TUNEL-positive rate, cleaved caspase-3, and cleaved poly(adenosine 5'-diphosphate-ribose) polymerase expression and decreased Bcl-2 protein expression in cultured leiomyoma cells. These effects were dose and time dependent. In cultured myometrial cells, however, asoprisnil did not affect cell proliferation and apoptosis. PR-B expression was elevated in cultured leiomyoma cells compared with cultured myometrial cells, whereas no differences in PR-A expression were noted between the two cell types. Conclusions: These results show that asoprisnil inhibits proliferation and induces apoptosis in cultured uterine leiomyoma cells in the absence of comparable effects on cultured normal myometrial cells, suggesting a cell type-specific effect.
引用
收藏
页码:1296 / 1304
页数:9
相关论文
共 37 条
[1]   CHARACTERIZATION OF THE CELLULAR REDUCTION OF 3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE (MTT) - SUBCELLULAR-LOCALIZATION, SUBSTRATE DEPENDENCE, AND INVOLVEMENT OF MITOCHONDRIAL ELECTRON-TRANSPORT IN MTT REDUCTION [J].
BERRIDGE, MV ;
TAN, AS .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 303 (02) :474-482
[2]   PARP-1, a determinant of cell survival in response to DNA damage [J].
Bouchard, WJ ;
Rouleau, M ;
Poirier, GG .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (06) :446-454
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   PROGESTERONE-RECEPTOR MESSENGER-RIBONUCLEIC-ACID AND PROTEIN ARE OVEREXPRESSED IN HUMAN UTERINE LEIOMYOMAS [J].
BRANDON, DD ;
BETHEA, CL ;
STRAWN, EY ;
NOVY, MJ ;
BURRY, KA ;
HARRINGTON, MS ;
ERICKSON, TE ;
WARNER, C ;
KEENAN, EJ ;
CLINTON, GM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 169 (01) :78-85
[5]   AN EVALUATION OF THE EFFECT OF GONADOTROPIN-RELEASING-HORMONE ANALOGS AND MEDROXYPROGESTERONE ACETATE ON UTERINE LEIOMYOMATA VOLUME BY MAGNETIC-RESONANCE-IMAGING - A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER TRIAL [J].
CARR, BR ;
MARSHBURN, PB ;
WEATHERALL, PT ;
BRADSHAW, KD ;
BRESLAU, NA ;
BYRD, W ;
ROARK, M ;
STEINKAMPF, MP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (05) :1217-1223
[6]  
Chwalisz K, 2005, ENDOCR REV, V26, P703
[7]   Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis [J].
Chwalisz, K ;
Perez, MC ;
DeManno, D ;
Winkel, C ;
Schubert, G ;
Elger, W .
ENDOCRINE REVIEWS, 2005, 26 (03) :423-438
[8]   The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women [J].
Chwalisz, K ;
Elger, W ;
Stickler, T ;
Mattia-Goldberg, C ;
Larsen, L .
HUMAN REPRODUCTION, 2005, 20 (04) :1090-1099
[9]   Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. [J].
Chwalisz, K ;
Mattia-Goldberg, C ;
Lee, M ;
Elger, W ;
Edmonds, A .
FERTILITY AND STERILITY, 2004, 82 :S83-S84
[10]  
Chwalisz K, 2004, J SOC GYNECOL INVEST, V11, p320A